# Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

> **NCT01188850** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Human Papillomavirus (HPV)

## Interventions

- **BIOLOGICAL:** VGX-3100

## Key facts

- **NCT ID:** NCT01188850
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-10
- **Final completion:** 2011-10-20
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188850, "Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01188850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*